

MammaPrint Clinical Utility

High 2 Risk

Agendia's MammaPrint® 70-gene test enables clinicians to identify women* with a genomically High 2 Risk of recurrence that clinical studies have demonstrated as having a significantly higher rate of pCR when treated neoadjuvantly.

MAMMAPRINT INDEX



Guiding Neoadjuvant Chemotherapy Treatment Decisions

NEOADJUVANT CHEMOTHERAPY CONSIDERATIONS WITH MAMMAPRINT HIGH 2 RISK RESULT

	NBRST	I-SPY2	FLEX																		
Treatment	AC-T, T-AC, or TC	AC-T	TC or AC-T																		
Total patients who received NCT	327	299	214																		
Total MammaPrint High 2 Risk patients who received NCT	129	166	72																		
pCR MammaPrint High 2 Risk patients who received NCT	<table border="1"> <tr> <th>Risk Category</th> <th>pCR Rate</th> </tr> <tr> <td>High 1</td> <td>6.1%</td> </tr> <tr> <td>High 2</td> <td>23.3%</td> </tr> </table>	Risk Category	pCR Rate	High 1	6.1%	High 2	23.3%	<table border="1"> <tr> <th>Risk Category</th> <th>pCR Rate</th> </tr> <tr> <td>High 1</td> <td>10.0%</td> </tr> <tr> <td>High 2</td> <td>22.0%</td> </tr> </table>	Risk Category	pCR Rate	High 1	10.0%	High 2	22.0%	<table border="1"> <tr> <th>Risk Category</th> <th>pCR Rate</th> </tr> <tr> <td>High 1</td> <td>6.3%</td> </tr> <tr> <td>High 2</td> <td>29.2%</td> </tr> </table>	Risk Category	pCR Rate	High 1	6.3%	High 2	29.2%
Risk Category	pCR Rate																				
High 1	6.1%																				
High 2	23.3%																				
Risk Category	pCR Rate																				
High 1	10.0%																				
High 2	22.0%																				
Risk Category	pCR Rate																				
High 1	6.3%																				
High 2	29.2%																				

Beitsch et al, ASCO 2023

Pusztai et al, Cancer Cell, 2021

O'Shaughnessy et al, SABCs 2023

* 18 years or older